81 FR 90194 - Establishment of a New Drug Code for Marihuana Extract
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 81, Issue 240 (December 14, 2016)
Drug Enforcement Administration
Federal Register Volume 81, Issue 240 (December 14, 2016)
| Page Range | 90194-90196 | |
| FR Document | 2016-29941 |
[Federal Register Volume 81, Number 240 (Wednesday, December 14, 2016)] [Rules and Regulations] [Pages 90194-90196] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-29941] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-342] RIN 1117-AB33 Establishment of a New Drug Code for Marihuana Extract AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final rule. ----------------------------------------------------------------------- SUMMARY: The Drug Enforcement Administration is creating a new Administration Controlled Substances Code Number for ``Marihuana Extract.'' This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions. Under international drug control treaties administered by the United Nations, some differences exist between the regulatory controls pertaining to marihuana extract versus those for marihuana and tetrahydrocannabinols. The DEA has previously established separate code numbers for marihuana and for tetrahydrocannabinols, but not for marihuana extract. To better track these materials and comply with treaty provisions, DEA is creating a separate code number for marihuana extract with the following definition: ``Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.'' Extracts of marihuana will continue to be treated as Schedule I controlled substances. DATES: Effective: January 13, 2017. FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone (202) 598- 6812. SUPPLEMENTARY INFORMATION: Background As provided in 21 CFR 1308.03, each controlled substance or basic class thereof is assigned a four digit Administration Controlled Substance Code Number (``Code number'' or ``drug code'') that is used to track quantities of the controlled substance imported and exported to and from the United States. Additionally, the DEA uses these code numbers in establishing aggregate production quotas for basic classes of controlled substances listed in Schedules I and II as required by 21 U.S.C. 826. Consistent with the Controlled Substances Act (CSA), the schedules contained in DEA regulations include marihuana (drug code 7360) in Schedule I. 21 CFR 1308.11(d)(23). This listing includes (unless specifically excepted or unless listed in another schedule) any material, compound, mixture, or preparation, which contains any quantity of the substance, or which contains any of its salts, isomers, and salts of isomers that are possible within the specific chemical designation. Because the definition of marihuana in 21 U.S.C. 802(16) includes both derivatives and preparations of marihuana, the DEA until now has used drug code 7360 for extracts of marihuana. This final rule finalizes a [[Page 90195]] July 5, 2011, Notice of Proposed Rulemaking (76 FR 39039) in which the DEA proposed that a new drug code 7350 be used for extracts of marihuana. Why a New Code Number Is Needed The United Nations Conventions on international drug control treats extracts from the cannabis plant somewhat differently than marihuana or tetrahydrocannabinols. The creation of a new drug code in the DEA regulations for marihuana extracts will allow for more appropriate accounting of such materials consistent with treaty provisions. The Single Convention on Narcotic Drugs, 1961 (``Single Convention'') and the 1971 Convention on Psychotropic Substances (``Psychotropic Convention'') provide for the international control of marihuana constituents. Many of the CSA's provisions were drafted to comply with these Conventions. The CSA includes schemes of drug scheduling and procedures for adding, removing, and transferring drugs among the schedules that are similar, in some ways, to those in the Single Convention. With respect to those drugs that are subject to control under the Single Convention, the CSA mandates that DEA control such drugs in a manner that will ensure the United States meets its obligations under the Single Convention. 21 U.S.C. 811(d)(1). Somewhat similar to the CSA, the Single Convention lists substances in four schedules. However, under the Single Convention, the drugs that are subject to the most stringent controls are in Schedule IV. Another difference between the CSA and the Single Convention is that, under the latter, a drug can be listed in more than one schedule. Cannabis and cannabis resin are listed in both Schedule IV and Schedule I of the Single Convention. Schedule I controls under the Single Convention include: Requirements for import and export authorization, licensing of manufacturers/distributors, recordkeeping requirements, a requirement for prescriptions for medical use, annual estimate of needs, quotas, annual statistical reporting, and a requirement that use be limited to medical and scientific purposes. Schedule II of the Single Convention is similar in controls to Schedule I with a few exceptions, and Schedule III is less restrictive. All substances listed in Schedule IV are also listed in Schedule I under the Single Convention in order to encompass the requirements mentioned above. In addition, as indicated, the Single Convention imposes certain heightened measures of control with respect to Schedule IV drugs. The placing of a drug into both Schedule I and Schedule IV, therefore imposes the most stringent controls under the Single Convention. Although cannabis and cannabis resin are listed in Schedules I and IV of the Single Convention, cannabis extracts are listed only in Schedule I. Comments In response to the July 5, 2011, Notice of Proposed Rulemaking (76 FR 39039), the DEA received six submissions from five commenters. Three of the comments raised issues relating to the medical use or legality of marihuana/cannabis; these comments were not germane to the issues addressed by this rulemaking. A fourth comment was merely a clarification of a comment previously submitted. One comment requested clarification of whether the new drug code will be applicable to cannabidiol (CBD), if it is not combined with cannabinols. DEA response: For practical purposes, all extracts that contain CBD will also contain at least small amounts of other cannabinoids.\1\ However, if it were possible to produce from the cannabis plant an extract that contained only CBD and no other cannabinoids, such an extract would fall within the new drug code 7350. In view of this comment, the regulatory text accompanying new drug code 7350 has been modified slightly to make clear that it includes cannabis extracts that contain only one cannabinoid. --------------------------------------------------------------------------- \1\ Although it might be theoretically possible to produce a CBD extract that contains absolutely no amounts of other cannabinoids, the DEA is not aware of any industrially-utilized methods that have achieved this result. --------------------------------------------------------------------------- Another comment from a pharmaceutical firm currently involved in cannabinoid research and product development praised DEA's efforts to establish a new drug code for marihuana extracts as a means to more accurately reflect the activities of scientific research and provide more consistent adherence to the requirements of the Single Convention. However, the comment expressed concerns that the proposed definition for the new drug code (i.e. ``meaning extracts that have been derived from any plant of the genus Cannabis and which contain cannabinols and cannabidiols'') is too narrow. The comment suggested that the broader term ``cannabinoids'' be substituted for ``cannabinols and cannabidiols.'' The comment pointed out that other constituents of the marihuana plant may have therapeutic potential. The comment further clarified that the broader term ``cannabinoid'' includes both cannabinol-type compounds and cannabidiol-type compounds, as well as cannabichromene-type compounds, cannabigerol-type compounds, and other categories of compounds. DEA response: DEA agrees with the commenter that the term ``cannabinoid'' would provide for a broader definition of marihuana extract; however, use of the term ``cannabinoid'' necessitates that the DEA clarify that the new marihuana extract category (drug code 7350) is not intended to include ``cannabis resin'' as defined in the U.N. Single Convention. As discussed in the NPRM, a new drug code is necessary in order to better account for these materials in accordance with treaty obligations. The Single Convention placed ``cannabis'' and ``cannabis resin'' under both Schedule I and IV of the Convention, the most stringent level of control under the Convention. While ``cannabis resin'' is extracted from ``cannabis,'' the Single Convention specifically controls ``extracts'' separately. Extracts of cannabis are controlled only under Schedule I of the Convention, which is a lower level of control than ``cannabis resin.'' Accordingly, it is the DEA's intent to define the term ``marihuana extract'' so as to exclude material referenced as ``cannabis resin'' under the Single Convention on Narcotics. ``Cannabis resin'' (regulated under the CSA as a resin of marihuana) contains a variety of ``cannabinoids'' and will continue to be regulated as marihuana under drug code 7360. The new drug code for marihuana extracts under 21 CFR 1308.11(d)(58) will exclude the resin. Cannabis resin and marihuana resin remain captured under the drug code for marihuana (drug code 7360), thus differentiating this material from marihuana extracts (new drug code 7350). This will maintain compliance with the Single Convention. Final Action After careful consideration of all comments, the DEA is hereby amending 21 CFR 1308.11(d) to include a new subparagraph (58) which creates a new code number in Schedule I as follows: ``(58) Marihuana Extract--7350 ``Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.'' The creation of this new drug code in the DEA regulations for marihuana extracts allows for more appropriate accounting of such materials consistent with treaty provisions. Such marihuana [[Page 90196]] extracts remain in Schedule I. Entities registered to handle marihuana (under drug code 7360) that also handle marihuana extracts, will need to apply to modify their registrations to add the new drug code 7350 to their existing DEA registrations and procure quotas specifically for drug code 7350 each year. Regulatory Analyses Executive Orders 12866 and 13563, Regulatory Planning and Review, and 13563, Improving Regulation and Regulatory Review This regulation has been drafted and reviewed in accordance with the principles of Executive Orders 12866 and 13563. This rule is not a significant regulatory action under Executive Order 12866. Executive Order 12988, Civil Justice Reform This regulation meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 to eliminate drafting errors and ambiguity, minimize litigation, provide a clear legal standard for affected conduct, and promote simplification and burden reduction. Executive Order 13132, Federalism This rulemaking does not have federalism implications warranting the application of Executive Order 13132. The rule does not have substantial direct effects on the States, on the relationship between the national government and the States, or the distribution of power and responsibilities among the various levels of government. Executive Order 13175, Consultation and Coordination With Indian Tribal Governments This rule does not have tribal implications warranting the application of Executive Order 13175. It does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes. Regulatory Flexibility Act The Administrator, in accordance with the Regulatory Flexibility Act (RFA), 5 U.S.C. 601-602, has reviewed this rule and by approving it, certifies that it will not have a significant economic impact on a substantial number of small entities. This rule establishes a new drug code for marihuana extracts. DEA already registers persons handling marihuana extracts but within another already-established drug code. Thus, persons who handle these marihuana extracts have already met DEA's registration, security, and other statutory and regulatory requirements. The only direct effect to registrants who handle marihuana extracts will be the requirement to add the new drug code to their registration. Therefore, DEA has concluded that this rule will not have a significant effect on a substantial number of small entities. Unfunded Mandates Reform Act of 1995 On the basis of information contained in the ``Regulatory Flexibility Act'' section above, DEA has determined and certifies pursuant to the Unfunded Mandates Reform Act (UMRA) of 1995, 2 U.S.C. 1501 et seq., that this action would not result in any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted for inflation) in any one year. Therefore, neither a Small Government Agency Plan nor any other action is required under provisions of the UMRA of 1995. Paperwork Reduction Act of 1995 This action does not impose a collection of information requirement under the Paperwork Reduction Act of 1995. 44 U.S.C. 3501-3521. This action would not impose recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Congressional Review Act This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act (CRA)). This rule will not result in: An annual effect on the economy of $100,000,000 or more; a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of U.S.-based companies to compete with foreign based companies in domestic and export markets. However, pursuant to the CRA, the DEA has submitted a copy of this final rule to both Houses of Congress and to the Comptroller General. List of Subjects in 21 CFR Part 1308 Drug traffic control, Controlled substances. For the reasons set out above, 21 CFR part 1308 is amended as follows: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0 1. The authority citation for part 1308 continues to read as follows: Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted. 0 2. Section 1308.11 is amended by adding paragraph (d)(58) to read as follows: Sec. 1308.11 Schedule I. * * * * * (d) * * * (58) Marihuana Extract--(7350) Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant. * * * * * Dated: December 7, 2016. Chuck Rosenberg, Acting Administrator. [FR Doc. 2016-29941 Filed 12-13-16; 8:45 am] BILLING CODE 4410-09-P
![90194 Federal Register / Vol. 81, No. 240 / Wednesday, December 14, 2016 / Rules and Regulations
FDA performs to monitor third-party third-party certification bodies, would from quantities of marihuana. This, in
certification bodies that are accredited remain in effect. turn, will aid in complying with
by a recognized accreditation body (3) If payment is not received within relevant treaty provisions.
under § 1.662. 90 days of the payment due date, FDA Under international drug control
will revoke the accreditation body’s treaties administered by the United
§ 1.710 How will FDA notify the public recognition under § 1.634(a)(4)(iii), and Nations, some differences exist between
about the fee schedule?
provide notice of such revocation in the regulatory controls pertaining to
FDA will notify the public of the fee accordance with § 1.634. marihuana extract versus those for
schedule annually. The fee notice will (c) An accredited third-party marihuana and tetrahydrocannabinols.
be made publicly available prior to the certification body that fails to submit its The DEA has previously established
beginning of the fiscal year for which annual fee within 30 days of the due separate code numbers for marihuana
the fees apply, except for the first fiscal date will have its accreditation and for tetrahydrocannabinols, but not
year in which this regulation is suspended. for marihuana extract. To better track
effective. Each new fee schedule will be (1) FDA will notify the third-party these materials and comply with treaty
adjusted for inflation and improvements certification body that its accreditation provisions, DEA is creating a separate
in the estimates of the cost to FDA of is suspended, electronically and in code number for marihuana extract with
performing relevant work for the English. FDA will notify a recognized the following definition: ‘‘Meaning an
upcoming year. accreditation body, electronically and in extract containing one or more
§ 1.715 When must a user fee required by English, if the accreditation of one if its cannabinoids that has been derived
this subpart be submitted? third-party certification bodies is from any plant of the genus Cannabis,
suspended. FDA will notify the public other than the separated resin (whether
(a) Accreditation bodies applying for crude or purified) obtained from the
of the suspension on the Web site
recognition and third-party certification plant.’’ Extracts of marihuana will
described in § 1.690.
bodies applying for direct accreditation continue to be treated as Schedule I
(2) While a third-party certification
must submit a fee concurrently with controlled substances.
body’s accreditation is suspended, the
submitting an application or a renewal
third-party certification body will not be DATES: Effective: January 13, 2017.
application.
able to issue food or facility FOR FURTHER INFORMATION CONTACT:
(b) Accreditation bodies and third- certifications. A food or facility
party certification bodies subject to an Michael J. Lewis, Office of Diversion
certification issued by a third-party Control, Drug Enforcement
annual fee must submit payment within certification body prior to the
30 days of receiving billing for the fee. Administration; Mailing Address: 8701
suspension of the auditor/certification Morrissette Drive, Springfield, Virginia
§ 1.720 Are user fees under this subpart body accreditation will remain in effect. 22152; Telephone (202) 598–6812.
refundable? (3) If payment is not received within SUPPLEMENTARY INFORMATION:
User fees accompanying completed 90 days of the payment due date, FDA
will withdraw the third-party Background
applications and annual fees under this
subpart are not refundable. certification body’s accreditation under As provided in 21 CFR 1308.03, each
§ 1.664(a)(4), and provide notice of such controlled substance or basic class
§ 1.725 What are the consequences of not withdrawal in accordance with § 1.664. thereof is assigned a four digit
paying a user fee under this subpart on Administration Controlled Substance
Dated: December 9, 2016.
time?
Leslie Kux, Code Number (‘‘Code number’’ or ‘‘drug
(a) An application for recognition or code’’) that is used to track quantities of
Associate Commissioner for Policy.
renewal of recognition will not be the controlled substance imported and
[FR Doc. 2016–30033 Filed 12–13–16; 8:45 am]
considered complete for the purposes of exported to and from the United States.
BILLING CODE 4164–01–P
§ 1.631(a) until the date that FDA Additionally, the DEA uses these code
receives the application fee. An numbers in establishing aggregate
application for direct accreditation or production quotas for basic classes of
for renewal of direct accreditation will DEPARTMENT OF JUSTICE controlled substances listed in
not be considered complete for the Schedules I and II as required by 21
purposes of § 1.671(a) until FDA Drug Enforcement Administration
U.S.C. 826.
receives the application fee. Consistent with the Controlled
(b) A recognized accreditation body 21 CFR Part 1308
Substances Act (CSA), the schedules
that fails to submit its annual user fee [Docket No. DEA–342] contained in DEA regulations include
within 30 days of the due date will have marihuana (drug code 7360) in
its recognition suspended. RIN 1117–AB33 Schedule I. 21 CFR 1308.11(d)(23). This
(1) FDA will notify the accreditation listing includes (unless specifically
Establishment of a New Drug Code for
body electronically that its recognition excepted or unless listed in another
Marihuana Extract
is suspended. FDA will notify the schedule) any material, compound,
public of the suspension on the Web site AGENCY: Drug Enforcement mixture, or preparation, which contains
described in § 1.690. Administration, Department of Justice. any quantity of the substance, or which
(2) While an accreditation body’s ACTION: Final rule. contains any of its salts, isomers, and
recognition is suspended, the salts of isomers that are possible within
accreditation body will not be able to SUMMARY: The Drug Enforcement the specific chemical designation.
rmajette on DSK2TPTVN1PROD with RULES
accredit additional third-party Administration is creating a new Because the definition of marihuana in
certification bodies. The accreditation of Administration Controlled Substances 21 U.S.C. 802(16) includes both
third-party certification bodies that Code Number for ‘‘Marihuana Extract.’’ derivatives and preparations of
occurred prior to an accreditation This code number will allow DEA and marihuana, the DEA until now has used
body’s suspension, as well as food or DEA-registered entities to track drug code 7360 for extracts of
facility certifications issued by such quantities of this material separately marihuana. This final rule finalizes a
VerDate Sep<11>2014 15:29 Dec 13, 2016 Jkt 241001 PO 00000 Frm 00010 Fmt 4700 Sfmt 4700 E:\FR\FM\14DER1.SGM 14DER1](https://thefederalregister.org/doc/81_FR_90434/page/1.svg)
![90196 Federal Register / Vol. 81, No. 240 / Wednesday, December 14, 2016 / Rules and Regulations
extracts remain in Schedule I. Entities extracts but within another already- List of Subjects in 21 CFR Part 1308
registered to handle marihuana (under established drug code. Thus, persons Drug traffic control, Controlled
drug code 7360) that also handle who handle these marihuana extracts substances.
marihuana extracts, will need to apply have already met DEA’s registration,
to modify their registrations to add the security, and other statutory and For the reasons set out above, 21 CFR
new drug code 7350 to their existing regulatory requirements. The only direct part 1308 is amended as follows:
DEA registrations and procure quotas effect to registrants who handle PART 1308—SCHEDULES OF
specifically for drug code 7350 each marihuana extracts will be the CONTROLLED SUBSTANCES
year. requirement to add the new drug code
Regulatory Analyses to their registration. Therefore, DEA has ■ 1. The authority citation for part 1308
concluded that this rule will not have a continues to read as follows:
Executive Orders 12866 and 13563, significant effect on a substantial
Regulatory Planning and Review, and Authority: 21 U.S.C. 811, 812, 871(b),
number of small entities. unless otherwise noted.
13563, Improving Regulation and
Regulatory Review Unfunded Mandates Reform Act of 1995 ■ 2. Section 1308.11 is amended by
This regulation has been drafted and On the basis of information contained adding paragraph (d)(58) to read as
reviewed in accordance with the in the ‘‘Regulatory Flexibility Act’’ follows:
principles of Executive Orders 12866 section above, DEA has determined and § 1308.11 Schedule I.
and 13563. This rule is not a significant certifies pursuant to the Unfunded
* * * * *
regulatory action under Executive Order Mandates Reform Act (UMRA) of 1995,
(d) * * *
12866. 2 U.S.C. 1501 et seq., that this action
would not result in any Federal (58) Marihuana Extract—(7350)
Executive Order 12988, Civil Justice Meaning an extract containing one or
mandate that may result in the
Reform more cannabinoids that has been
expenditure by State, local, and tribal
This regulation meets the applicable governments, in the aggregate, or by the derived from any plant of the genus
standards set forth in sections 3(a) and private sector, of $100,000,000 or more Cannabis, other than the separated resin
3(b)(2) of Executive Order 12988 to (adjusted for inflation) in any one year. (whether crude or purified) obtained
eliminate drafting errors and ambiguity, Therefore, neither a Small Government from the plant.
minimize litigation, provide a clear legal Agency Plan nor any other action is * * * * *
standard for affected conduct, and required under provisions of the UMRA
promote simplification and burden Dated: December 7, 2016.
of 1995.
reduction. Chuck Rosenberg,
Paperwork Reduction Act of 1995 Acting Administrator.
Executive Order 13132, Federalism
This action does not impose a [FR Doc. 2016–29941 Filed 12–13–16; 8:45 am]
This rulemaking does not have
collection of information requirement BILLING CODE 4410–09–P
federalism implications warranting the
under the Paperwork Reduction Act of
application of Executive Order 13132.
1995. 44 U.S.C. 3501–3521. This action
The rule does not have substantial DEPARTMENT OF LABOR
would not impose recordkeeping or
direct effects on the States, on the
reporting requirements on State or local
relationship between the national Occupational Safety and Health
governments, individuals, businesses, or
government and the States, or the Administration
organizations. An agency may not
distribution of power and
conduct or sponsor, and a person is not
responsibilities among the various 29 CFR Part 1988
required to respond to, a collection of
levels of government.
information unless it displays a [Docket Number: OSHA–2015–0021]
Executive Order 13175, Consultation currently valid OMB control number.
and Coordination With Indian Tribal RIN 1218–AC88
Governments Congressional Review Act
Procedures for Handling Retaliation
This rule does not have tribal This rule is not a major rule as
Complaints Under Section 31307 of the
implications warranting the application defined by section 804 of the Small
Moving Ahead for Progress in the 21st
of Executive Order 13175. It does not Business Regulatory Enforcement
Century Act (MAP–21)
have substantial direct effects on one or Fairness Act of 1996 (Congressional
more Indian tribes, on the relationship Review Act (CRA)). This rule will not AGENCY: Occupational Safety and Health
between the Federal Government and result in: An annual effect on the Administration, Labor.
Indian tribes, or on the distribution of economy of $100,000,000 or more; a ACTION: Final rule.
power and responsibilities between the major increase in costs or prices for
Federal Government and Indian tribes. consumers, individual industries, SUMMARY: On March 16, 2016, the
Federal, State, or local government Occupational Safety and Health
Regulatory Flexibility Act agencies, or geographic regions; or Administration (OSHA) of the U.S.
The Administrator, in accordance significant adverse effects on Department of Labor (Department)
with the Regulatory Flexibility Act competition, employment, investment, issued an interim final rule (IFR) that
(RFA), 5 U.S.C. 601–602, has reviewed productivity, innovation, or on the provided procedures for the
this rule and by approving it, certifies ability of U.S.-based companies to Department’s processing of complaints
rmajette on DSK2TPTVN1PROD with RULES
that it will not have a significant compete with foreign based companies under the employee protection
economic impact on a substantial in domestic and export markets. (retaliation or whistleblower) provisions
number of small entities. This rule However, pursuant to the CRA, the DEA of Section 31307 of the Moving Ahead
establishes a new drug code for has submitted a copy of this final rule for Progress in the 21st Century Act
marihuana extracts. DEA already to both Houses of Congress and to the (MAP–21). The IFR established
registers persons handling marihuana Comptroller General. procedures and time frames for the
VerDate Sep<11>2014 15:29 Dec 13, 2016 Jkt 241001 PO 00000 Frm 00012 Fmt 4700 Sfmt 4700 E:\FR\FM\14DER1.SGM 14DER1](https://thefederalregister.org/doc/81_FR_90434/page/3.svg)
Document Created: 2016-12-14 00:48:20
Document Modified: 2016-12-14 00:48:20
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Rules and Regulations | |
| Action | Final rule. | |
| Dates | Effective: January 13, 2017. | |
| Contact | Michael J. Lewis, Office of Diversion | |
| FR Citation | 81 FR 90194 | |
| RIN Number | 1117-AB33 | |
| CFR Associated | Drug Traffic Control and Controlled Substances |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR